Capped U.S. prescription drug prices are still double that of other wealthy countries. Here’s why

A study by the nonprofit RAND Corp looking at 2022 prescription prices found that U.S. health plans paid more than three times as much for brand-name pharmaceuticals, even after estimated discounts.

The U.S. government’s first-ever negotiated prices for prescription drugs are still on average more than double, and in some cases five times, what drugmakers have agreed to in four other high-income countries, a Reuters review has found.